Novel Therapeutic Agents in Waldenström’s Macroglobulinemia

Within the past few years, major advances in the preclinical and clinical testing of novel therapeutic agents have occurred in Waldenström’s macroglobulinemia (WM). These include agents that target the PI3K/Akt/mTOR pathway, PKC pathways, NF-kB signaling pathway, as well as tyrosine kinases and hist...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Ghobrial, Irene M., Leleu, Xavier, Azab, Abdel Kareem, Runnels, Judith, Jia, Xiaoying, Ngo, Hai, Melhem, Molly, Azab, Feda, Sacco, Antonio, Quang, Phong, Burwick, Nicholas, Moreau, Anne-Sophie, Husu, Emanuel, Farag, Mena, Roccaro, Aldo
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2009
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3133646/
https://ncbi.nlm.nih.gov/pubmed/19362982
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3816/CLM.2009.n.022
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi